Asset
DIMETHYL FUMARATE
Revenue
No revenue reported in loaded filings.
Clinical trials (34)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00837785 | phase1 | completed | 2009-02-28 | 2009-10-31 | Biogen | A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS |
| NCT01930708 | phase4 | completed | 2013-10-31 | 2016-03-31 | Biogen | A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes |
| NCT05658484 | phase4 | completed | 2023-06-09 | 2025-03-27 | Biogen | A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China |
| NCT07483632 | phase3 | not_yet_recruiting | 2026-11-16 | 2034-07-28 | Biogen | A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS) |
| NCT01281111 | phase1 | completed | 2011-02-01 | 2011-03-18 | Biogen | Alternate Dosing Regimens of BG00012 in Healthy Volunteers |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 204063 | NDA | BIOGEN INC |
Marketed products (2)
- TECFIDERA
- TECFIDERA